Skip to main content

Pressmeddelanden 1 träff

AstraZeneca announces top-line results from phase III monotherapy study of lesinurad in gout patients

Pressmeddelanden   •   Dec 13, 2013 08:16 CET

AstraZeneca today announced top-line results from LIGHT, a Phase III study investigating the potential of lesinurad as a monotherapy in the small population of gout patients who are intolerant to, or otherwise cannot take, one or both xanthine oxidase inhibitors allopurinol and febuxostat.